ClouDr Group Limited (HK:9955) has released an update.
ClouDr Group Limited has announced the signing of a License Agreement, which grants them an exclusive, sub-licensable license to use certain intellectual property for product development, manufacturing, and sales within a specified territory. The agreement, effective from June 23, 2024, also allows ClouDr to sublicense and modify the products, conduct clinical trials, and manage trademarks related to the products. This strategic move is set to enhance ClouDr’s market presence and product portfolio.
For further insights into HK:9955 stock, check out TipRanks’ Stock Analysis page.
